Post-operative autologous transfusion of filtered shed blood in total knee arthroplasty: clinical bloodmanagement in everyday orthopaedic practice

Autologous blood transfusion after total knee arthroplasty

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

NL-OMON

Registry ID

NL-OMON21964

Enrollment

750

Registered

2014-08-11

Start date

2014-08-18

Completion date

Unknown

Last updated

2024-02-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

TKA, transfusion, blood, autoloog

Interventions

Total knee arthroplasty (TKA) is associated with considerable blood loss, which may lead to post-operative anemia. To compensate for this blood loss, blood transfusions are sometimes necessary. Althou

Eligibility

Inclusion criteria

Inclusion criteria: - Patients undergoing primary TKA - Surgery between January 2010 and December 2011

Exclusion criteria

Exclusion criteria: - Secondary total knee arthroplasty - Rheumatoid arthritis (RA) - Missing data regarding: a. necessity and amount of autologous blood transfusion b. necessity of allogeneic blood transfusion

Design outcomes

Primary

Measure	Time frame
Primary outcome: -Peri-operative Hb levels: oStandard measurement moments are: „XWithin 24 hours pre-operative. Usually the evening before surgery or the same morning before surgery. „XOne day post-operative „XThree days post-operative	—

Secondary

Measure	Time frame
Secondary outcomes: - Allogeneic blood transfusion in the postoperative period. The indication for allogeneic blood transfusion and amount of administered blood is registered in the EPD and is available for analysis. In our analysis we will mainly look at necessity of allogeneic blood transfusion in relation to whether a retransfusion system was applied (i.e. dichotomous variables). Differences in the units of packed cells administered will be analysed. - Length of hospitalisation o Normal length of stay after TKA is 3-5 days. Data will be collected from the EPD to analyse any prolonged or reduced length of stay. Any prolonged or reduced length of stay will then be analysed to check for possible complications. - Complications. o Events that have affected the overall patient outcome, required revision surgery or increased length of stay will be defined as postoperative complications. General non specific complications such as gastrointestinal-, urinary tract-, respiratory- or cardiac complications are not going to be included in the analysis but will be described. - Amount of autologous blood transfused. The amount of retransfused blood (ml) is registered in our EPD.	—

Measure

Time frame

Secondary outcomes: - Allogeneic blood transfusion in the postoperative period. The indication for allogeneic blood transfusion and amount of administered blood is registered in the EPD and is available for analysis. In our analysis we will mainly look at necessity of allogeneic blood transfusion in relation to whether a retransfusion system was applied (i.e. dichotomous variables). Differences in the units of packed cells administered will be analysed. - Length of hospitalisation o Normal length of stay after TKA is 3-5 days. Data will be collected from the EPD to analyse any prolonged or reduced length of stay. Any prolonged or reduced length of stay will then be analysed to check for possible complications. - Complications. o Events that have affected the overall patient outcome, required revision surgery or increased length of stay will be defined as postoperative complications. General non specific complications such as gastrointestinal-, urinary tract-, respiratory- or cardiac complications are not going to be included in the analysis but will be described. - Amount of autologous blood transfused. The amount of retransfused blood (ml) is registered in our EPD.

—

Contacts

Public ContactM.G.M. Schotanus

Department of Orthopedic Surgery, Orbis Medisch Centrum dr H vd Hoffplein 1

m.schotanus@orbisconcern.nl+31 (0)88 4597823

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP)